Introduction Introduction Introduction Introduction
• Cyclin dependent kinases (Cdks) not only drive cell cycle progression, but also control transcription. For example, Cdk7 and Cdk9 phosphorylate the Ser2 and Ser5 sites, respectively, on the C-terminal domain (CTD) of RNA polymerase II (pol II) to promote transcription initiation and elongation.
• • Here we studied a novel Cdk inhibitor SNS-032, a 2-aminothiazole derivative with potent and selective inhibitory activity against Cdk2, Cdk7 and Cdk9.
• SNS-032, formerly known as BMS-387032, is currently in a Phase 1 trial in patients with chronic lymphocytic leukemia and multiple myeloma. SNS-032 is administered using a pharmacologicallyderived dose regimen, designed to sustain levels above 0.3 µM for over 6 hours, the EC 90 concentration and time required for in vitro cytotoxicity.
SNS-032
Recovery of CLL cells after washing into fresh medium without SNS-032 • After washing away SNS-032 at 6 hr, the percentage of cell death remained at the level of 6 hr, whereas continued incubation for 24 hr induced greater cell death.
SNS-032 inhibits RNA synthesis
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Inhibition of Cdks by SNS-032 and flavopiridol N=6
• •SNS-032 at 0.1 µ µ µ µM inhibits RNA synthesis by >80% at 6 hr.
•SNS-032 is ~10-30 fold more potent than flavopiridol at inhibiting RNA synthesis. 
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